14437
document
Perioperative immunotherapy with recombinant interleukin 2 in patients undergoing surgery for colorectal cancer . Major surgery impairs the cellular immune response . We have therefore studied the immunological effects of low-dose recombinant interleukin 2 given to patients undergoing surgery for colorectal cancer to determine whether this agent has potential in perioperative adjuvant immunotherapy . Patients were randomly allocated to control ( n = 13 ) or treatment groups ( n = 12 ) . Immunological studies of both lymphocyte function and subset number were performed preoperatively and on Days 1 , 4 , 7 , and 10 . Treatment with recombinant interleukin 2 prevented the postoperative fall in both natural killer and lymphokine-activated killer cell cytotoxicity , clearly demonstrated in the control group . The treatment group also showed in vivo T-cell activation with an initial lymphopenia followed by a rebound lymphocytosis and upregulation of the subset markers CD25 ( interleukin 2 receptor ) and CD45RO ( T-memory cells ) . These combined effects may have important consequences in controlling metastatic dissemination of tumor during the vulnerable perioperative period .
14438
Intervention_Pharmacological
recombinant interleukin 2
14439
Intervention_Pharmacological
low-dose recombinant interleukin 2
14440
Intervention_Control
control
14441
Intervention_Pharmacological
recombinant interleukin 2
14442
Outcome_Physical
lymphocyte function
14443
Outcome_Physical
natural killer and lymphokine-activated killer cell cytotoxicity
14444
Outcome_Physical
vivo T-cell activation
14445
Outcome_Physical
rebound lymphocytosis
14446
Outcome_Physical
upregulation of the subset markers CD25 ( interleukin 2 receptor )
14447
Outcome_Physical
CD45RO ( T-memory cells )
14448
Participant_Condition
patients undergoing surgery for colorectal cancer .